FORM PTO-1449

Att. Docket No. 710A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

IAY 1 8 2005 gApplicant:

Nicholas J. Papadopoulos et al.

Serial No.

: 10/009,852

Date Filed

December 6, 2001

For

Modified Chimeric Polypeptides with

Improved Pharmacokinetic Properties

and Methods of Making and Using

Thereof

Examiner

Hunnicutt, Rachel K. Lockard, Jon M.

Group Art Unit

1647

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

OTHER DOCUMENTS

Examiner	
Initials	
m C	Holash, J., et al. (2002) PNAS, Vol. 99, No. 17, pp. 11393-11398.
	Heidaran, M.A., (1990) The Journal of Biological Chemistry, Vol. 265, No. 31, Issue of November 5, pp. 18741-18744.
+	Cunningham, S.A. et al., (1997) Biochemical and Biophysical Research Communications, Vol. 231, pp.596-599.
	Fuh, G. et al. (1998) The Journal of Biological Chemistry, Vol. 273, No. 18, Issue of May 1, pp. 11197-11204.
1	Wiesmann, C. et al. (1997) Cell, Vol. 91, pp. 695-704.
ome	Barleon, B. et al. (1997) The Journal of Biological Chemistry, Vol. 272. No. 16, pp. 10382-10388.

Son M Jalel

8/30/05

710A-US U.S. Serial No. 10/009,852 PTO 1449 Form Papadopoulos et al. Page 2

mc

Davis-Smyth, T. et al. (1998) The Journal of Biological Chemistry, Vol. 273, No. 6, pp. 3216-3222.

EXAMINER CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Valeta Gregg Reg. No. 35,127

Attorneys for Applicant Patent Agent for Applicant Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591

(914) 345-7400